new symp banner

Featured Speakers

Symposium 2024
Suzanne McGurn
Suzanne McGurn

President and Chief Executive Officer, Canada's Drug Agency

Sessions >
  • Official Opening
  • Opening Plenary: Introducing Canada’s Drug Agency
Sudha Kutty
Sudha Kutty

Executive Vice-President, Evidence, Products, and Services, Canada's Drug Agency

Sessions >
  • Early Morning Session 1: Moving Beyond Opening a Window to Creating a Door
  • Panel Session 1: Innovation in the Pharmaceutical Ecosystem
  • Panel Session 9: Accelerating Access: Leveraging Target Zero to Expedite Time to Access for New Therapies
  • Panel Session 14: Improving Patient Safety and Outcomes: A Vision for a pan-Canadian Coordinated Approach to Appropriate Use
Dr. Nicole Mittmann
Dr. Nicole Mittmann

Chief Scientist and Vice President, Scientific Evidence, Methodologies and Resources, Canada's Drug Agency

Sessions >
  • Special Session 4: Canada’s Drug Agency Initiatives in Drugs for Rare Diseases
  • Early Morning Session 1: Moving Beyond Opening a Window to Creating a Door
  • Panel Session 12: Advancing Patient Engagement and Impact in Canada's Drug Agency Deliberative Process: A Multistakeholder Collaboration
  • Closing Plenary: From Disruption to Opportunity: Implementing AI and Other Innovations
Dr. Kwadwo Kyeremanteng
Dr. Kwadwo Kyeremanteng

Department Head of Critical Care, The Ottawa Hospital

Sessions >
  • Symposium Dinner
Kate Harback
Kate Harback

CEO and Executive Director, Institute of Health Economics

Sessions >
  • Early Morning Session 2: Operationalizing Outcomes-Based Agreements in Canada
Mina Tadrous
Mina Tadrous

Assistant Professor, Leslie Dan Faculty of Pharmacy, University of Toronto

Sessions >
  • Early Morning Session 3: The Growing Problem of Drug Shortages: Understanding Their Impact on Research, Patients, and Health Care Systems
Guillaume Couillard
Guillaume Couillard

Executive Director, Patented Medicine Prices Review Board

Sessions >
  • Opening Plenary: Introducing Canada’s Drug Agency
Patrick Dicerni
Patrick Dicerni

Assistant Deputy Minister Health Programs and Delivery Division and Executive Office, Ontario Public Drug Programs, Ontario Ministry of Health and Long-Term Care

Sessions >
  • Opening Plenary: Introducing Canada’s Drug Agency
Daniel Ollendorf
Daniel Ollendorf
 

Chief Scientific Officer and Director of HTA Methods Development, ICER
 

Sessions >
  • Early Morning Session 8: What’s New in US HTA? A Snapshot of ICER’s Value Assessment Framework Update
  • Closing Plenary: From Disruption to Opportunity: Implementing AI and Other Innovations
Marina Richardson
Marina Richardson
 

Associate Director, HTA Methods and Health Economics, ICER

Sessions >
 
  • Early Morning Session 8: What’s New in US HTA? A Snapshot of ICER’s Value Assessment Framework Update
  • Panel Session 13: Closing the Gap Or Widening The Divide: Do We Need a Framework for Truly Embedding Equity in Health Technology Assessment (HTA)?
Dr. Nick Crabb
Dr. Nick Crabb

Chief Scientific Officer, National Institute for Health and Care Excellence (NICE)

Sessions >
  • Closing Plenary: From Disruption to Opportunity: Implementing AI and Other Innovations
Pascale Lehoux
Pascale Lehoux

Vice-Présidente Scientifique, INESSS

Sessions >
  • Oral Presentations 5: An Actionable and Legible Toolbox for the Appraisal of Health Care Innovations Developed Through Provincial Stakeholder Collaboration
  • Closing Plenary: From Disruption to Opportunity: Implementing AI and Other Innovations
Shawn Paron
Shawn Paron

Chief Operating Officer, Alzheimer Society of Ontario

Sessions >
  • Early Morning Session 5: Real-World Evidence (RWE): Empowering Patient Advocacy Groups to Co-Design Registries That Fill a Data Gap for Their Community
Bonnie Macfarlane
Bonnie Macfarlane

Associate Director, Health Technology Assessment, Submissions and Analytics, Janssen Inc

Sessions >
  • Panel session 12: Advancing Patient Engagement and Impact in Canada's Drug Agency Deliberative Process: A Multistakeholder Collaboration
Don Husereau
Don Husereau

Adjunct Professor, SEPH, University of Ottawa

Sessions >
  • Workshop 4: An Introduction to Health Technology Assessment
  • Panel Session 4: Breaking Barriers: Tackling Challenges in Mental Health Drug Health Technology Assessments
Beth Kidd
Beth Kidd

Executive Director, Health Coalition of Alberta 

Sessions >
  • Opening Plenary: Introducing Canada’s Drug Agency
  • Panel Session 9: Accelerating Access: Leveraging Target Zero to Expedite Time to Access for New Therapies
Bettina Hamelin
Bettina Hamelin

President, Innovative Medicines Canada

Sessions >
  • Opening Plenary: Introducing Canada’s Drug Agency
Daniel MacDonald
Daniel MacDonald

Director General, Office of Pharmaceutical Management Strategies, Strategic Policy Branch, Health Canada

Sessions >
  • Opening Plenary: Introducing Canada’s Drug Agency
Dr. Avram Denburg
Dr. Avram Denburg

Staff Oncologist and Clinician-Scientist in the Division of Haematology/Oncology, SickKids

Sessions >
  • Workshop 3: Unlocking Ethics in HTA: Exploring Practice and Impact
Dr. Jim Silvius
Dr. Jim Silvius

Chair, Canadian Drug Expert Committee (CDEC)

Sessions >
  • Panel Session 14: Improving Patient Safety and Outcomes: A Vision for a pan-Canadian Coordinated Approach to Appropriate Use
Dr. Muhammad Mamdani
Dr. Muhammad Mamdani

Vice President - Data Science and Advanced Analytics, Unity Health Toronto

Sessions >
  • Closing Plenary: From Disruption to Opportunity: Implementing AI and Other Innovations
 
Dominic Tan
Dominic Tan

Acting CEO, pan-Canadian Pharmaceutical Alliance

Sessions >
  • Opening Plenary: Introducing Canada’s Drug Agency